- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 52 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 14.04. | ELICERA THERAPEUTICS: Green light to continue Elicera's CARMA-trial in B-cell lymphoma | 2 | Cision News | ||
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 189 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | 3 | Cision News | ||
| 13.03. | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters | 1 | Cision News | ||
| 07.03. | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025 | 2 | Cision News | ||
| 03.03. | ELICERA THERAPEUTICS: Elicera's CEO: "TO2 is a highly attractive opportunity to increase ownership in Elicera" | 2 | Cision News | ||
| 28.02. | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 2 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.02. | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 1 | Cision News | ||
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 312 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 25.02. | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million | 1 | Cision News | ||
| 25.02. | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85 | 2 | Cision News | ||
| 12.02. | Elicera Therapeutics receives partial payment of 0,5 MEur from EIC | 3 | Cision News | ||
| 12.02. | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme | 2 | Cision News | ||
| 10.02. | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans | 8 | Cision News | ||
| 05.02. | ELICERA THERAPEUTICS: Elicera's CEO: "2025 is a crucial year for us" | 1 | Cision News | ||
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 109 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.01. | ELICERA THERAPEUTICS: Elicera's CEO: "All signs of the disease disappeared in the first patient" | 1 | Cision News | ||
| 21.01. | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference | 2 | Cision News | ||
| 15.01. | ELICERA THERAPEUTICS: Elicera's candidate ELC-100 granted Orphan Drug Designation | 4 | Cision News |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,976 | -1,22 % | Evotec-Aktie mit leichten Kursgewinnen (7,086 €) | Im Plus liegt derzeit das Wertpapier von Evotec . Zuletzt zahlten Investoren für das Wertpapier 7,09 Euro. Am deutschen Aktienmarkt hat sich heute die Evotec-Aktie zwischenzeitlich um 2,99 Prozent verteuert.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 520,40 | +1,64 % | Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock | ||
| BRAIN BIOTECH | 2,130 | +1,91 % | Brain Biotech: Schwaches Jahresviertel | Im zweiten Quartal sinkt der Umsatz bei Brain Biotech um 16 Prozent auf 12,12 Millionen Euro. Das bereinigte EBITDA steht bei -0,36 Millionen Euro. Für das Gesamtjahr nimmt die Gesellschaft ihre Prognose... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 0,950 | -3,94 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| BURCON NUTRASCIENCE | 0,063 | -1,56 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CSL | 136,16 | -0,26 % | Are CSL shares at risk from the Trump tariffs? | ||
| MANNKIND | 4,012 | -3,65 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,500 | -1,19 % | Oxford Nanopore CFO participates in share incentive plan | ||
| OCULAR THERAPEUTIX | 6,120 | -1,45 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,220 | -10,57 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business Update | TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45... ► Artikel lesen | |
| CODEXIS | 2,150 | -2,98 % | Stifel maintains Buy rating on Codexis stock with $5 target | ||
| TELO GENOMICS | 0,053 | -8,62 % | Telo Genomics Corp.: European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress | Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,260 | -100,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth | Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora... ► Artikel lesen | |
| CORMEDIX | 10,500 | 0,00 % | CorMedix Inc. (CRMD): Among Billionaire Paul Singer's Stock Picks with Huge Upside Potential |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,421 Euro und damit -1,17 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.